Background
In this report, we discuss how autoimmune conditions and associated immunocompromise may impact diagnostic utility of molecular screening tools for mycobacterial infection. Imaging, molecular screening and clinical judgement are required to rule out disease in the immunocompromised, especially in an acute setting.1,2.